US2916417A - Article of manufacture - Google Patents
Article of manufacture Download PDFInfo
- Publication number
- US2916417A US2916417A US630086A US63008656A US2916417A US 2916417 A US2916417 A US 2916417A US 630086 A US630086 A US 630086A US 63008656 A US63008656 A US 63008656A US 2916417 A US2916417 A US 2916417A
- Authority
- US
- United States
- Prior art keywords
- dicyclopropyl
- ketoxime
- article
- per
- skeletal muscle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- YNMFDPCLPIMRFD-UHFFFAOYSA-N Quercetin-3-o-vicianoside Chemical compound OC1C(O)C(O)COC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 YNMFDPCLPIMRFD-UHFFFAOYSA-N 0.000 claims description 26
- 210000002027 skeletal muscle Anatomy 0.000 claims description 11
- 239000003158 myorelaxant agent Substances 0.000 claims description 9
- 231100000252 nontoxic Toxicity 0.000 claims description 9
- 230000003000 nontoxic effect Effects 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 238000000034 method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010049816 Muscle tightness Diseases 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 229920002261 Corn starch Polymers 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 206010021118 Hypotonia Diseases 0.000 description 4
- 239000011149 active material Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000036640 muscle relaxation Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007971 pharmaceutical suspension Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003186 pharmaceutical solution Substances 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 244000007645 Citrus mitis Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- LZXXNPOYQCLXRS-UHFFFAOYSA-N methyl 4-aminobenzoate Chemical compound COC(=O)C1=CC=C(N)C=C1 LZXXNPOYQCLXRS-UHFFFAOYSA-N 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- NBFQYHKHPBMJJV-UHFFFAOYSA-N risocaine Chemical compound CCCOC(=O)C1=CC=C(N)C=C1 NBFQYHKHPBMJJV-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
Definitions
- compositions of this invention employing dicyclopropyl ketoxime are highly effective muscle relaxants of the internuncial neuron depressant type. They have low toxicity and can be administered orally in dosage units of the size, type and kind to be described hereinafter.
- Dicyclopropyl ketoxime tablets Dicyclopropyl ketoxime (1.33 pounds) is mixed with 37.31 pounds of lactose and passed through a 30-mesh screen.
- a starch paste is prepared using 1.05 pounds of corn starch and 5.98 pounds of distilled water. The starch paste is massed with the prior mixture and passed through a 4-mesh screen and then dried at F. for 17 hours. The dried paste is granulated and passed through a 16 screen.
- Stearic acid (0.446 pound), corn starch (3.87 pounds) and talc (2.036 pounds) are passed through a 40-rnesh screen and blended well with the granulated dicyclopropyl ketoxime, lactose and corn starch.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
United States Patent ARTICLE OF MANUFACTURE Bruce W. Horrom, Waukegan, Ill., assigmor to Abbott Laboratories, North Chicago, Ill., a corporation of Illinois No Drawing. Application December 24, 1956 Serial No. 630,086
8 Claims. (Cl. 167-65) This invention relates to a new article of manufacture and to methods of compounding and using the same. More particularly, the invention relates to the compound dicyclopropyl ketoxime in a dosage unit form suitable for use as a muscle relaxant.
The compound dicyclopropyl ketoxime has the following structural formula 1l\lr01-1 M It is a white crystalline solid material that is sparingly soluble in water up to a level of 0.5%, and highly soluble in organic solvents such as benzene, ether, alcohol and the like. It has a boiling point of 141-146" C. (60 mm.) and when recrystallized from petroleum solvent, the solid material has a melting point of 76-77 C.
The method for preparing dicyclopropyl ketoxime has been described by H. Hart and O. E. Curtis, Jr., J.A.C.S., volume 78, page 112 (1956).
The muscle relaxant properties refer to relief of skeletal muscle tension and spasms by interrupting synaptic transmissions at various levels of the central nervous cord rather than interrupting peripheral nervous impulses at the myoneural junction of skeletal muscle, thus distinguishing their mode of action from curare-like drugs.
It is the object of this invention to provide convenient dosage unit forms of a compound having marked muscle relaxant properties, in particular dosage unit forms of the compound dicyclopropyl ketoxime.
Another object is to prepare said dosage forms in solid and liquid carriers suitably selected for either oral or injectable administration.
It has now been found that the compositions of this invention employing dicyclopropyl ketoxime are highly effective muscle relaxants of the internuncial neuron depressant type. They have low toxicity and can be administered orally in dosage units of the size, type and kind to be described hereinafter.
The effective clinical dose of dicyclopropyl ketoxime for adults ranges from about 100 mg. per day upwardly. In children the dosage ranges correspondingly lower according to the age and Weight of the child. The drug may be administered in the forms of tablets, capsules, powder or in a flavored suspension or solution. A preferred form of administration is in scored tablets each containing 10 mg. of drug, which will provide the minimum dose for children when broken in half, and when taken in multiples will provide amounts up to the maximum dose.
In one of the preferred compositions the active ingredient, dicyclopropyl ketoxime, may be incorporated into tablets by utilizing standard ingredients and steps in the preparation thereof. In particular, solid diluents and "ice tableting adjuvants such as corn starch, acacia, lactose, talc, stearic acid, magnesium stearate, gums and the like may be used. Any of the tableting materials used in the pharmaceutical art may be employed where there is no incompatibility with the active material. Alternatively, the active material with or without its adjuvant materials may be placed in a soft or hard gelatin capsule and administered in capsule form.
In another embodiment of the invention a solution dose form is made. Although solubility in water is low (0.5%), a sufficient concentration of dicyclopropyl ke toxime can be dissolved to provide a therapeutic dosage. A solution dosage form can contain from about 2 mg. per cc. (10 mg. per teaspoon) to about 5 mg. per cc. of the active ingredient. Should a liquid dosage form containing a greater concentration of the active material be desired, a suspension of dicyclopropyl ketoxime may be prepared by compounding the active ingredient in concentration above about 5 mg. per cc. of liquid with suspending agents such as acacia or carboxymethylcellulose along with the usual flavoring materials. Such a liquid preparation is particularly suitable for children and infirm persons who have difliculty swallowing a tablet or capsule.
The following examples illustrate preferred embodiments of the dosage forms, but it should be understood that they are not meant to restrict the dosage forms to ingredients and proportions named therein.
EXAMPLE I Dicyclopropyl ketoxime tablets Dicyclopropyl ketoxime (1.33 pounds) is mixed with 37.31 pounds of lactose and passed through a 30-mesh screen. A starch paste is prepared using 1.05 pounds of corn starch and 5.98 pounds of distilled water. The starch paste is massed with the prior mixture and passed through a 4-mesh screen and then dried at F. for 17 hours. The dried paste is granulated and passed through a 16 screen. Stearic acid (0.446 pound), corn starch (3.87 pounds) and talc (2.036 pounds) are passed through a 40-rnesh screen and blended well with the granulated dicyclopropyl ketoxime, lactose and corn starch.
The blended material is compressed into tablets each containing 10 mg. of active material.
EXAMPLE II Dicyclopropyl ketoxime in solution dose form A pharmaceutical solution of dicyclopropyl ketoxime is prepared by combining the following ingredients:
Dicyclopropyl ketoxime gms 2.0 Sucrose gms 200.0 Glucose gms" 250.0 Glycerin cc 50.0 Methyl-p-aminobenzoate -gms- 1.5 Propyl-p-aminobenzoate gms 0.15 F.D. & C. orange #1 gms 0.05 Imitation orange aroma cc 0.02 Oil orange cc 0.5 Water, Ilco, q.s. cc 1000.0
The foregoing solution provides a concentration of active ingredient at a level of 2 mg. per cc. or 10 mg. per teaspoon.
The esters of p-hydroxybenzoic acid prevent fermentation and mold formation.
3 EXAMPLE n1 Dicyclopropyl ketoxime in suspension dose form A pharmaceutical suspension of dicyclopropyl ketoxime is prepared by combining the following ingredicuts:
The foregoing suspension provides a concentration of active ingredient at a level of 10 mg. per cc. or 50 mg. per teaspoon.
While the foregoing preparations are designed for oral administration, appropriate solutions or suspensions containing dicyclopropyl ketoxime may be devised for injectable introduction into the body. The term injectable introduction is intended to include all the routes available to this form of dosage, namely intravenous, intramuscular and intraperitoneal. Such injectable compositions resemble the product of Example II except that the sugars, flavors, colors and glycerin are replaced with an equivalent amount of water.
Others may practice the invention in any of the numerous ways which will be suggested by this disclosure to one skilled in the art. vention is considered to be a part hereof provided it falls within the scope of the appended claims.
I claim:
1. An article of manufacture characterized by skeletal muscle relaxant activity comprising at least about 10 mg. of dicyclopropyl ketoxime and a non-toxic pharmaceutical carrier.
All such practice of the in- 2. An article of manufacture characterized by skeletal muscle relaxant activity comprising at least about 10 mg. of dicyclopropyl ketoxime and a non-toxic solid pharmaceutical carrier in dosage unit form.
3. An article of manufacture characterized by skeletal muscle relaxant activity comprising an aqueous liquid pharmaceutical carrier containing at least about 2 mg. of dicyclopropyl ketoxime per cc. of liquid.
4. A composition characterized by skeletal muscle relaxant activity comprising an aqueous pharmaceutical suspension including a non-toxic suspending agent and at least about 5 mg. per cc. of dicyclopropyl ketoxime.
5. The method of causing muscle relaxation in persons subject to excessive skeletal muscle tension which comprises administering to the human host a non-toxic composition containing at least about 10 mg. of dicyclopropyl ketoxime.
6. The method of causing skeletal muscle relaxation in a living host afilicted with excessive muscle tension which comprises administering orally to the living host a non-toxic composition comprising at least about 10 mg. of dicyclopropyl ketoxime and a pharmaceutical carrier.
7. The method of causing skeletal muscle relaxation in a living host afilicted with excessive tension which comprises administering by injection a non-toxic pharmaceutical solution containing at least about 2 mg./cc. of dicyclopropyl ketoxime.
8. The method of causing skeletal muscle relaxation in a living host afilicted with excessive muscle tension which comprises administering orally to the living host a non-toxic, aqueous pharmaceutical suspension containing at least about 5 mg./cc. of dicyclopropyl ketoxime and a non-toxic suspending agent.
References Cited in the file of this patent Colman et al.: Ber. Deut. Chem, vol. 19 (II), 1896, pp. 3113-3114.
UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION Patent Non 2,916,417 December 8, 1959 Bruce W, Horrom appears in the printed specification It is hereby certified that error correct-ion and that the said Letters of the above numbered patent requiring Patent should read as corrected below.
Column 4, line 24, for excessive tension" read excessive' muscle tension Signed and sealed this 24th day of May 1960,
(SEAL) Attest:
KARL AXLINE Attesting @mcer ROBERT C. WATSON Commissioner of Patents
Claims (1)
1. AN ARTICLE OF MANUFACTURE CHARACTERIZED BY SKELETAL MUSCLE RELAXANT ACTIVITY COMPRISING AT LEAST ABOUT 10 MG. OF DICYCLOPROPYL KETOXIME AND A NON-TOXIC PHARMACEUTICAL CARRIER.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US630086A US2916417A (en) | 1956-12-24 | 1956-12-24 | Article of manufacture |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US630086A US2916417A (en) | 1956-12-24 | 1956-12-24 | Article of manufacture |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US2916417A true US2916417A (en) | 1959-12-08 |
Family
ID=24525684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US630086A Expired - Lifetime US2916417A (en) | 1956-12-24 | 1956-12-24 | Article of manufacture |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US2916417A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3117987A (en) * | 1959-09-04 | 1964-01-14 | Abbott Lab | Dicyclopropylketoxime derivatives |
| US3127415A (en) * | 1961-08-14 | 1964-03-31 | Mead Johnson & Co | 3-substituted-3-pyrrolidinols |
| US3143466A (en) * | 1962-02-01 | 1964-08-04 | Colgate Palmolive Co | Nu-(beta-halopropionyl)-piperidines as cns depressants |
| US5508302A (en) * | 1994-09-28 | 1996-04-16 | American Home Products Corporation | Phospholipase A2 inhibitors |
-
1956
- 1956-12-24 US US630086A patent/US2916417A/en not_active Expired - Lifetime
Non-Patent Citations (1)
| Title |
|---|
| None * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3117987A (en) * | 1959-09-04 | 1964-01-14 | Abbott Lab | Dicyclopropylketoxime derivatives |
| US3127415A (en) * | 1961-08-14 | 1964-03-31 | Mead Johnson & Co | 3-substituted-3-pyrrolidinols |
| US3143466A (en) * | 1962-02-01 | 1964-08-04 | Colgate Palmolive Co | Nu-(beta-halopropionyl)-piperidines as cns depressants |
| US5508302A (en) * | 1994-09-28 | 1996-04-16 | American Home Products Corporation | Phospholipase A2 inhibitors |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3873879T2 (en) | NON-SEDATIVE ANTIHISTAMINICA CONTAINING COUGH / SNUGS. | |
| JPS62215527A (en) | Alzheimer's sclerosis remedy | |
| JP3192141B2 (en) | Antidepressant | |
| IE911989A1 (en) | Antimalarial Compositions | |
| US2890984A (en) | Pharmaceutical composition containing 2-(1, 2, 3, 4-tetrahydro-1-naphthyl)imidazo-line | |
| CZ282679B6 (en) | The use of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole for preparing a pharmaceutical preparation | |
| US2916417A (en) | Article of manufacture | |
| US3144387A (en) | Anti-inflammatory compositions | |
| US2953494A (en) | 2-amino-1-(3, 4-methylenedioxyphenyl)-propane isomers, ataractic preparation containing 2-amino-1-(3, 4-methylenedioxyphenyl)-propane and method of producing ataraxia | |
| US2817623A (en) | Tabernanthine, ibogaine containing analgesic compositions | |
| US2853418A (en) | Hypnotic composition comprising a barbiturate and beta, beta-methyl ethyl glutarimide | |
| US2910403A (en) | Anti hypertensive compositions comprising 2-methyl-5, 8-dimethoxychromone and acetamides | |
| ES2349996T3 (en) | PREPARATION OF DELAYED RELEASE IN THE FORM OF PELLS CONTAINING CINARIZINE AND DIMENHYDRINATE AGAINST THE VESSEL. | |
| CN105919991A (en) | Application of euparin to preparation of medicine for treating depression | |
| JPH10338631A (en) | Anti-anxiety agent | |
| US3360434A (en) | Method for reducing blood pressure with phenylalanine derivatives | |
| US2995491A (en) | Method of treating cardiac arrhythmia with 1-(2-diethylaminoethyl)-5-ethyl-5-phenylbarbituric acid | |
| US2799617A (en) | Piperazine adipate compositions and treatment of helminth infections therewith | |
| US2793157A (en) | Anticonvulsant 3-ethyl-5-phenyl hydantoin unit dosages and method of using same | |
| US3864486A (en) | Therapeutic compositions of bromazepam and sulpiride | |
| US2995489A (en) | Method of obtaining preanesthetic sedation and drying with 1-(2-diethylaminoethyl)-5-ethyl-5-phenylbarbituric acid | |
| US3138529A (en) | Tetracycline antibiotic compositions for oral use | |
| US2991225A (en) | Omicron-methylbenzhydryl-beta-dimethylaminoethyl ether process and composition for symptomatic relief of the syndrome of parkinsonism and of spastic skeletal muscle disorders | |
| US3053731A (en) | Therapeutic composition containing 4, 6-dimethyl-3-pyridazone and process of inducing hypnosis and tranquilization therewith | |
| JPH0232020A (en) | Method and drug for suppressing manifestation of tolerance in morphine analgestic treatment |